by The global CRISPR & Cas genes market size was estimated at USD 3.67 billion in 2024 and is projected to surpass around USD 17.49 billion by 2034, growing at a CAGR of 16.90%.
Get Sample Copy of Report@ https://www.precedenceresearch.com/sample/1108
Key Points
- North America dominated the global market in 2024 with a 39% market share.
- Asia Pacific is expected to experience the highest CAGR throughout the forecast period.
- The biomedical segment accounted for the largest market share by application in 2024.
- Among product and service categories, the product segment generated the highest revenue in 2024.
- The biotechnology and pharmaceutical segment emerged as the leading end-user in 2024.
Drivers
The CRISPR & Cas genes market is primarily driven by the increasing demand for gene editing technologies in medical research and therapeutic applications. The rising prevalence of genetic disorders and chronic diseases such as cancer has fueled the need for advanced gene therapy solutions.
The growing investment in biotechnology and pharmaceutical research by governments and private organizations is also accelerating market growth. Furthermore, the advancements in CRISPR-based diagnostics and treatments are expanding its use in various applications, from drug development to agriculture.
Opportunities
The potential of CRISPR technology in personalized medicine presents significant opportunities for market expansion. With the ability to precisely modify genetic sequences, CRISPR-based therapies are paving the way for customized treatments for hereditary and rare diseases.
Additionally, the increasing adoption of CRISPR in agriculture for crop improvement and pest resistance offers new revenue streams. The growing collaboration between research institutions and biotech companies is further driving innovation, leading to the development of next-generation CRISPR tools with enhanced accuracy and efficiency.
Challenges
Despite its promising applications, the CRISPR & Cas genes market faces several challenges, including ethical concerns related to human genome editing. Regulatory restrictions and stringent approval processes for gene-editing therapies also pose hurdles to market growth.
Additionally, unintended genetic mutations and off-target effects remain key concerns, limiting the widespread adoption of CRISPR-based treatments. High costs associated with CRISPR research and development further add to the market’s challenges, making accessibility an issue, particularly in developing regions.
Regional Analysis
North America holds the largest share of the CRISPR & Cas genes market, supported by strong research and development initiatives, high funding for genetic engineering projects, and the presence of leading biotechnology firms. Europe follows closely due to increasing government support for gene-editing research and advancements in precision medicine.
The Asia-Pacific region is expected to experience the highest growth, driven by rising investments in biotechnology, expanding healthcare infrastructure, and increasing demand for innovative genetic therapies. Latin America and the Middle East & Africa are gradually emerging as potential markets, with improving access to genetic research and healthcare innovations.
CRISPR & Cas Genes Market Companies
- Caribou Biosciences, Inc.
- F. Hoffmann-La Roche Ltd.
- Cellectis
- AstraZeneca
- Editas Medicine, Inc.
- Addgene
- Egenesis
- Horizon Discovery Group Plc
- Intellia Therapeutics, Inc.
- Genscrip
- Danaher Corporation
- Lonza
- Merck KGaA
- Synthego
- Mammoth Biosciences
- Inscripta, Inc.
- Cibus
- New England BioLabs
- Takara Bio, Inc.
Segments Covered in the Report
By Product & Service
- By Service
- Microbial Gene Editing
- Cell Line Engineering
- gRNA Design
- DNA Synthesis
- By Product
- Design Tool
- Kits & Enzymes
- Libraries
- Antibodies
- Others
By Application
- Agricultural
- Biomedical
- Functional Genomics
- Genome Engineering
- Disease Model Studies
- Epigenetics
- Others
End-use Outlook
-
- Contract Research Organizations (CROs),
- Academics & Government Research Institutes
- Biotechnology & Pharmaceutical Companies
By Regional Outlook
- North America
- U.S.
- Canada
- Europe
- U.K.
- Germany
- France
- Asia Pacific
- China
- India
- Japan
- South Korea
- Middle East & Africa
- Latin America
Ready for more? Dive into the full experience on our website@ https://www.precedenceresearch.com/
